Education
About Us
Working with TipRanks
Follow Us
Vyne Therapeutics Inc (VYNE)
:VYNE
VYNE Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VYNE Stock 12 Month Forecast
Average Price Target
$5.25
▲(483.33%Upside)
| Highest Price Target$6.00 | Average Price Target$5.25 | Lowest Price Target$4.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$1
Hold
11.11%
Upside
Reiterated
06/13/25
VYNE Therapeutics' overall stock score is primarily influenced by its weak financial performance and valuation challenges. Persistent losses and cash flow issues significantly impact its financial score, while negative technical indicators reflect bearish market sentiment. The lack of profitability further exacerbates valuation concerns, leading to a low overall score.
LifeSci Capital
$6
Buy
566.67%
Upside
Reiterated
05/08/25
H.C. Wainwright
$4.5
Buy
400.00%
Upside
Reiterated
05/08/25
BTIG
$8
Buy
788.89%
Upside
Reiterated
03/06/25
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (NASDAQ: VYNE), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Xtant Medical Holdings (NYSE MKT: XTNT)We continue to see room for Tx options with improved efficacy and safety in vitiligo and reviewed the opportunity in detail in our VYNE initiation. VYN202 (oral BD2-selective BET inhibitor) is progressing through a Phase 1b trial in moderate-to- severe plaque psoriasis with 12wk topline data expected by YE25. We view psoriasis as a well-suited steppingstone for VYN202 to demonstrate clinical PoC before moving into other I&I indications with common inflammatory pathways that could be addressed with BET inhibition (e.g., psoriatic arthritis, hidradenitis suppurativa, inflammatory bowel disease, and axial spondylarthritis). VYNE ended in cash and equivalents which the company is guiding as sufficient to fund operations into 2H26.
TD Cowen
$5
Buy
455.56%
Upside
Reiterated
02/20/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$1
Hold
11.11%
Upside
Reiterated
06/13/25
VYNE Therapeutics' overall stock score is primarily influenced by its weak financial performance and valuation challenges. Persistent losses and cash flow issues significantly impact its financial score, while negative technical indicators reflect bearish market sentiment. The lack of profitability further exacerbates valuation concerns, leading to a low overall score.
LifeSci Capital
$6
Buy
566.67%
Upside
Reiterated
05/08/25
H.C. Wainwright
$4.5
Buy
400.00%
Upside
Reiterated
05/08/25
BTIG
$8
Buy
788.89%
Upside
Reiterated
03/06/25
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (NASDAQ: VYNE), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Xtant Medical Holdings (NYSE MKT: XTNT)We continue to see room for Tx options with improved efficacy and safety in vitiligo and reviewed the opportunity in detail in our VYNE initiation. VYN202 (oral BD2-selective BET inhibitor) is progressing through a Phase 1b trial in moderate-to- severe plaque psoriasis with 12wk topline data expected by YE25. We view psoriasis as a well-suited steppingstone for VYN202 to demonstrate clinical PoC before moving into other I&I indications with common inflammatory pathways that could be addressed with BET inhibition (e.g., psoriatic arthritis, hidradenitis suppurativa, inflammatory bowel disease, and axial spondylarthritis). VYNE ended in cash and equivalents which the company is guiding as sufficient to fund operations into 2H26.
TD Cowen
$5
Buy
455.56%
Upside
Reiterated
02/20/25
Best Analysts Covering VYNE Therapeutics
1 Month
xxx
Success Rate
4/13 ratings generated profit
Average Return
-11.72%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 30.77% of your transactions generating a profit, with an average return of -11.72% per trade.
3 Months
xxx
Success Rate
4/13 ratings generated profit
Average Return
-15.59%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 30.77% of your transactions generating a profit, with an average return of -15.59% per trade.
1 Year
Success Rate
2/13 ratings generated profit
Average Return
-42.12%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -42.12% per trade.
2 Years
xxx
Success Rate
0/13 ratings generated profit
Average Return
-57.55%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -57.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VYNE Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
13
13
12
9
7
Buy
1
1
1
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
14
13
9
7
Each month's total comprises the sum of three months' worth of ratings.
VYNE Financial Forecast
VYNE Stock Forecast FAQ
What is VYNE’s average 12-month price target, according to analysts?
Based on analyst ratings, Vyne Therapeutics Inc’s 12-month average price target is 5.25.
What is VYNE’s upside potential, based on the analysts’ average price target?
Vyne Therapeutics Inc has 483.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VYNE a Buy, Sell or Hold?
Vyne Therapeutics Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Vyne Therapeutics Inc’s price target?
The average price target for Vyne Therapeutics Inc is 5.25. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $4.50. The average price target represents 483.33% Increase from the current price of $0.9.
The highest analyst price target is $6.00 ,the lowest forecast is $4.50. The average price target represents 483.33% Increase from the current price of $0.9.
What do analysts say about Vyne Therapeutics Inc?
Vyne Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of VYNE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.